Dexamethasone | Solubility of Things

Identification

Molecular formula

C₂₂H₂₉FO₅

CAS number

50-02-2

IUPAC name

(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one

State

At room temperature, dexamethasone is in a solid state. It is typically used in its powdered form but can be formulated into tablets, injections, and topical creams for medical use.

Melting point (Celsius)

262.00

Melting point (Kelvin)

535.15

Boiling point (Celsius)

393.45

Boiling point (Kelvin)

666.60

General information

Molecular weight

392.46g/mol

Molar mass

392.4610g/mol

Density

1.1570g/cm³

Appearence

Dexamethasone typically appears as a colorless to off-white crystalline powder. It is odourless and is often used in the form of salts for various applications.

Comment on solubility

Solubility of (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one

This compound exhibits _interesting_ solubility characteristics due to its complex structure. Understanding the solubility of such a multifaceted organic molecule is vital for its potential applications in pharmacology and materials science.

Solubility Factors

Several key factors influence the solubility of this compound:

Polarity: The presence of hydroxyl groups (–OH) generally increases solubility in polar solvents such as water, while the hydrocarbon regions may favor solubility in non-polar solvents.
Hydrogen Bonding: The ability to form hydrogen bonds can enhance the compound’s interaction with solvents, particularly in aqueous environments.
Sterics: The steric hindrance presented by bulky groups can also affect how easily the compound dissolves, impacting its accessibility to solvent molecules.
Hydrophilic vs. Hydrophobic Regions: A balance of hydrophilic (water-attracting) and hydrophobic (water-repelling) regions can lead to varying solubility across different solvents.

General Observations

While specific solubility data for this compound may be limited, one can relate its solubility behavior to similar compounds in its class:

Solubility in organic solvents: Typically, more soluble in non-polar organic solvents.
Solubility in water: Likely moderate solubility, influenced by the number of hydroxyl groups present.
Temperature dependence: As with many organic compounds, solubility may increase with temperature.

In summary, the solubility of (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one is a complex interplay of structural features. Understanding this multifaceted relationship can enable better predictions of its behavior in various chemical environments.

Interesting facts

Interesting Facts about (6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-Difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one

This complex compound, known for its structured framework, is a fascinating example of how intricate molecular arrangements can lead to significant biological activity. Here are some noteworthy points:

Steroid-like Framework: The compound has a steroid-like backbone, which is common in many biologically active molecules.
Fluorine Substituents: The presence of fluorine atoms can enhance the compound’s biological activity and metabolic stability, making it a prime candidate for pharmaceutical development.
Hydroxy Groups: The two hydroxy groups contribute to its potential hydrophilicity, influencing its interactions with biological systems.
Biological Activity: Such compounds often exhibit properties such as anti-inflammatory, anti-cancer, or antiviral effects, showcasing their potential in therapeutic applications.

Furthermore, its stereochemistry, indicated by the specific R and S configurations, plays a crucial role in the compound’s biological interactions. As chemists often say, “The function of a compound is influenced by its structure,” and this compound is a perfect illustration of that principle. Each stereocenter contributes to how this molecule orients itself in a biological environment, impacting how it interacts with enzymes and receptors within living organisms.

As a testament to its complexity and potential, research into compounds like this one continues to unveil new insights into medicinal chemistry and the development of novel therapeutics.

Synonyms

flumethasone

Flumetasone

Aniprime

Flucorticin

Flumethason

Anaprime

Methagon

Fluvet

Cortexilar

Flumetasona

RS 2177

Flumetasonum

Flumethasonum

6alpha-Fluorodexamethasone

6-alpha-Fluorodexamethasone

LR3CD8SX89

NSC 54702

RS-2177

6alpha,9alpha-Difluoro-16alpha-methylprednisolone

U-10974

DTXSID2045365

U-10,974

CHEBI:34764

EINECS 218-370-9

NSC-54702

Flumetasonum [INN-Latin]

UNII-LR3CD8SX89

Flumetasona [INN-Spanish]

BRN 5645455

DTXCID0025365

NSC54702

Flumetasonum (INN-Latin)

EC 218-370-9

Flumetasona (INN-Spanish)

Fluorodexamethasone

Bimasone

Flucort Tablets

Flucort Solution

Anaprime Suspension

flumethasoni pivalas

D07AB03

D07XB01

218-370-9

2135-17-3

Flumetasone [INN]

6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione

Flumethasone [USAN]

MLS000028618

(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one

C22H28F2O5

Flumetasone (INN)

Flumethasone (USAN)

SMR000058690

MFCD00056464

Flucort (Veterinary)

6.alpha.-Fluorodexamethasone

NCGC00016604-01

Prestwick_229

CAS-2135-17-3

Flumethasone (Standard)

Opera_ID_1501

Prestwick0_000734

Prestwick1_000734

Prestwick2_000734

Prestwick3_000734

FLUMETHASONE [MI]

6alpha-Fluoro-dexamethasone

SCHEMBL4046

BSPBio_000688

FLUMETASONE [WHO-DD]

MLS001077306

SPBio_002627

BPBio1_000758

6,9-Difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione

CHEMBL1201392

HY-B1051R

FLUMETHASONE [GREEN BOOK]

GLXC-20122

HMS1570C10

HMS2097C10

HMS2234B11

HMS3714C10

HY-B1051

Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,17,21-trihydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)-

Tox21_110518

s4088

AKOS005256462

AKOS015895435

Tox21_110518_1

AC-2069

CCG-220734

CS-4573

DB00663

FF23328

SMP1_000127

NCGC00021761-03

NCGC00021761-05

NCGC00021761-06

6alpha,9-Difluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione (Flumetasone)

6alpha,9alpha-Difluoro-16alpha-methyl-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione

AS-12534

Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,17,21-trihydroxy-16alpha-methyl-(VAN)

F0945

NS00001953

D04208

T72075

EN300-19734521

SR-01000003144

Q4383636

SR-01000003144-3

BRD-K61496577-001-03-8

BRD-K61496577-001-20-2

6.alpha., 9.alpha.-Difluoro-16.alpha.-methylprednisolone

(6a,11b,16a)-6,9-Difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione

(1R,2R,3aS,3bS,5S,9aS,9bR,10S,11aS)-5,9b-difluoro-1,10-dihydroxy-1-(2-hydroxyacetyl)-2,9a,11a-trimethyl-1H,2H,3H,3aH,3bH,4H,5H,7H,9aH,9bH,10H,11H,11aH-cyclopenta[a]phenanthren-7-one

(6alpha,11beta,16alpha)-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione

(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one

(6S,9R,10S,11S,13S,16R,17R)-6,9-Difluoro-11,17-dihydroxy-17-(2-hydroxy-acetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-cyclopenta[a]phenanthren-3-one

6.alpha., 9-Difluoro-11.beta.,17,21-trihydroxy-16.alpha.-methylpregna-1, 4-diene-3,20-dione

Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,17, 21-trihydroxy-16-methyl-, (6.alpha.,11.beta.,16.alpha.)-

Pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,17,21-trihydroxy-16.alpha.-methyl-